Neurocrine Biosciences
NBIX
NBIX
455 hedge funds and large institutions have $8.67B invested in Neurocrine Biosciences in 2023 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 165 increasing their positions, 185 reducing their positions, and 69 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
6% less funds holding
Funds holding: 484 → 455 (-29)
11% less repeat investments, than reductions
Existing positions increased: 165 | Existing positions reduced: 185
41% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 69
Holders
455
Holding in Top 10
11
Calls
$51.6M
Puts
$37.7M
Top Buyers
| 1 | +$78.4M | |
| 2 | +$73.1M | |
| 3 | +$71.1M | |
| 4 |
Man Group
London,
United Kingdom
|
+$59.5M |
| 5 |
IC
IEQ Capital
Foster City,
California
|
+$45.4M |
Top Sellers
| 1 | -$86.2M | |
| 2 | -$69.9M | |
| 3 | -$50.5M | |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$30.6M |
| 5 |
Renaissance Technologies
New York
|
-$28.6M |